Journal article

Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degeneration

Quan Dong Nguyen, Syed Mahmood Shah, Gulnar Hafiz, Diana V Do, Julia A Haller, Roberto Pili, Ingrid E Zimmer-Galler, Kashif Janjua, RC Andrew Symons, Peter A Campochiaro

AMERICAN JOURNAL OF OPHTHALMOLOGY | ELSEVIER SCIENCE INC | Published : 2008

Abstract

PURPOSE: To investigate the safety, tolerability, and bioactivity of intravenous infusions of bevacizumab in patients with choroidal neovascularization (CNV) attributable to causes other than age-related macular degeneration. DESIGN: Nonrandomized clinical trial. METHODS: Ten patients with CNV received infusions of 5 mg/kg of bevacizumab. The primary efficacy outcome measure was change in visual acuity (VA; Early Treatment Diabetic Retinopathy Study letters read at 4 meters) at 24 weeks and secondary measures were changes from baseline in excess foveal thickness (center subfield thickness), area of fluorescein leakage, and area of CNV. RESULTS: Infusions were well tolerated and there were no..

View full abstract

University of Melbourne Researchers